Selective chr21 homolog silencing reveals polymorphisms influence the epigenetic silencing and functional dosage of RWDD2B

Eric Larsen(University of Massachusetts Chan Medical School), Jeanne B. Lawrence(University of Massachusetts Chan Medical School), Jennifer Moon(Acuitas Therapeutics (Canada)), Oliver D. King(Boston Biomedical Research Institute)
bioRxiv (Cold Spring Harbor Laboratory)
September 18, 2025
10.1101/2025.09.17.676855
Cited by 0

Related Papers

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
PADGEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytes
|Cell|1989|877
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
|Cancer Cell|2012|722
Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains
|Cell|2018|487
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial
|The Lancet Oncology|2010|452